CS-3150

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hypertension

Conditions

Hypertension

Trial Timeline

Jun 1, 2016 → Mar 1, 2017

NCT ID

NCT02807974

About CS-3150

CS-3150 is a phase 3 stage product being developed by Daiichi Sankyo for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02807974. Target conditions include Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Hypertension were approved

Approved (20) Terminated (1) Active (0)

✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved

✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved

✅Amlodipine + ValsartanYuhanApproved

✅Duowell® + TelmisartanYuhanApproved

✅Olmesartan medoxomil + Losartan potassium + AtenololDaiichi SankyoApproved

✅olmesartan medoxomil + hydrochlorothiazide, if necessary + PlaceboDaiichi SankyoApproved

✅olmesartan medoxomil and a CCB + olmesartan medoxomil and a diureticDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02885662	Pre-clinical	Completed	Sep 1, 2016	Jul 20, 2017	Primary Aldosteronism
NCT02807974	Phase 3	Completed	Jun 1, 2016	Mar 1, 2017	Hypertension
NCT02808026	Phase 3	Completed	Jun 1, 2016	Feb 1, 2017	Severe Hypertension
NCT02807987	Phase 3	Completed	Jun 1, 2016	May 15, 2017	Hypertension With Moderate Renal Impairment
NCT02722265	Phase 3	Completed	Mar 1, 2016	Jul 8, 2017	Essential Hypertension
NCT02448628	Phase 2	Completed	May 1, 2015	Dec 1, 2015	Hypertension

Competing Products

20 competing products in Hypertension

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	32
tadalafil + tadalafil	Eli Lilly	Phase 3	40
CS1 Administration	Cereno Scientific	Phase 2	29
CS1	Cereno Scientific	Pre-clinical	24
TX000045- Dose A + TX000045- Dose B + Placebo	Tectonic Therapeutic	Phase 2	36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	25
Tirzepatide + Tirzepatide Placebo	Eli Lilly	Approved	50
L04RD1 + L04TD3	Celltrion	Phase 1	29
Azilsartan Medoxomil	Celltrion	Pre-clinical	26
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mg	Celltrion	Phase 3	40
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	39
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg	Yuhan	Approved	47
Telmisartan + Amlodipine + Chlorthalidone	Yuhan	Phase 1	29
Temisartan/Amlodipine+Rosuvastatin + YHP1604	Yuhan	Phase 1	29
Temisartan+Amlodipine+Rosuvastatin (Combination drug) + Temisartan+Amlodipine + Temisartan+Rosuvastatin	Yuhan	Phase 3	40
Amlodipine + Valsartan	Yuhan	Approved	43
Duowell® + Telmisartan	Yuhan	Approved	43
YHP1701 + YHR1703 + YHR1704	Yuhan	Phase 3	40
YH22189 + Twynsta 80/10mg + Crestor 20mg	Yuhan	Phase 1	21
OM 40 + OM/HCTZ 40/12.5	Daiichi Sankyo	Phase 3	40